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Abstract
Problem—The capacity of antigen-carrying vaccine nanoparticles administered vaginally to 
stimulate local immune responses may be limited by the relatively low numbers of antigen-
presenting cells (APCs) in the genital mucosa. Because inflammation is associated with increased 
susceptibility to sexually transmitted infections, we sought to increase APC numbers without 
causing inflammation.
Method of Study—In this study, we evaluated intravaginal delivery of chemokines, growth 
factors, or synthetic adjuvants to expand APCs in reproductive tissues.
Results—We found that granulocyte macrophage-colony stimulating factor (GM-CSF) 
stimulated expansion of CD11b+ dendritic cells within 24 h of intravaginal administration, with 
no effect on Langerhans cells or macrophages. Expansion of the CD11b+ DC population was not 
associated with increased inflammatory cytokine production, and these cells retained phagocytic 
function.
Conclusion—Our data suggest that non-inflammatory expansion of mucosal APCs by 
intravaginal GM-CSF could be used as an adjuvanting strategy to potentiate the genital immune 
response to nanoparticulate mucosal vaccines.
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Introduction
Overcoming the tightly down-regulated immune environment at mucosal sites has 
significant implications for the design of mucosal vaccines1. An additional challenge in the 
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lower female reproductive tract is the tissue's unique anatomy, including the limited network 
of lymphatic structures and secondary lymphoid structures, which restricts migration of 
immune cells in the absence of inflammation2-6. In general, this predisposes the female 
reproductive tract to weak immune responses to intravaginal vaccination.
Antigen presenting cells (APCs), specifically dendritic cells (DCs), are important for 
maintaining the balance between tolerance and pathogen-induced inflammation. A critical 
role for DCs in shaping genital immunity is suggested by the observation that strong 
adjuvants are required to boost genital immune responses to non-replicating subunit 
vaccines7,8. Since DCs are not a homogeneous population, targeting vaccines to specific DC 
subsets could allow effector T cell functions to be tailored to the relevant pathogen. 
However, targeting DCs is challenging given that they constitute a small fraction of cells in 
the vaginal mucosa, typically 5-10% of the cells in the basal vaginal epithelium and lamina 
propria of women without an active infection9. As such, strategies that recruit or expand 
mucosal DC subsets in situ may enhance immunity to vaginally administered vaccines.
Several approaches have been investigated to modulate DC numbers and activation state at 
immunization sites. Molecular adjuvants, such as the TLR9 agonist CpG, upregulate 
expression of co-stimulatory molecules10-13. Mucosal vaccines delivered in the presence of 
CpG induced cytokine secretion and increased infiltration of activated CD8+ T-cells14. 
Furthermore, intravaginally-delivered CpG transiently recruited MHC II+ CD11b+ antigen 
presenting cells to the vaginal submucosal15. However, molecular adjuvants like CpG cause 
strong, non-specific immune stimulation16,17. Such generalized inflammation can break 
down the natural mucosal barrier and recruit immune cells that serve as targets for mucosal 
pathogen transmission18,19.
In addition to synthetic adjuvants, cytokines or growth factors can be used to enhance DC 
populations in the mucosa. This strategy minimizes non-specific inflammation by 
specifically recruiting immature or precursor APCs. Chemokines, such as MIP-3α, can 
promote chemotaxis of APCs to the site of administration20-23. Growth factors, such as 
granulocyte-macrophage stimulating factor (GM-CSF), may specifically stimulate the 
differentiation of DCs from local undifferentiated monocytes24,25. In fact, recombinant GM-
CSF (Leukine®) is used in the clinic to reconstitute myeloid cell populations in blood after 
chemotherapy26,27.
In vaccination studies, GM-CSF alone and in combination with other cytokines has been 
shown to differentiate monocytes into fully functional DCs that can stimulate T cell immune 
responses. For example, in vivo transfection with a GM-CSF encoded plasmid successfully 
expanded liver CD11c+ dendritic cells that were highly efficient in priming T cells28. In 
CSF2-null mice, which cannot make GM-CSF, DCs and macrophages in the murine uterus 
express less MHC class II on their surface and are less effective in priming antigen-specific 
CD4+ and CD8+ T cells29. Cultures of PBMC with GM-CSF and other cytokines yields 
DCs that show high expression of HLA-DR and co-stimulatory molecules that efficiently 
present antigen and stimulate CD4+ T cell responses30-32. These results suggest that GM-
CSF is important for DC function.
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While many studies have evaluated the use of chemokines and growth factors in the context 
of systemic injections, few studies have evaluated their use for recruiting cells into the 
vaginal mucosa following topical administration. The need for mucosal adjuvants that 
modulate immunity in the reproductive mucosa motivates the discovery and application of 
agents that can expand key immune cell populations without causing concomitant local 
inflammation. Our goal is an intravaginal administration strategy focused on chemokine- or 
growth factor-mediated expansion of mucosal DCs. Here, we evaluate the numbers and 
phenotypes of mucosal DCs that arise from topical administration of a synthetic adjuvant 
(CpG) or a growth factor (GM-CSF), either alone or in combination with the chemokine 
MIP-3α, to the vaginal mucosa. Our results demonstrate that low doses of GM-CSF 
expanded in situ a functionally phagocytic mucosal DC population without eliciting 
inflammatory cytokine production. Furthermore, we show that GM-CSF specifically 
expanded CD11b+ dendritic cells but not Langerhans cells. Fluorescent nanoparticles 
administered intravaginally were phagocytosed by this mucosal DC population. Therefore, 
expanding functional DC subsets by topical administration of GM-CSF may be a promising 
strategy to potentiate protective immune responses to mucosal vaccines.
Materials and Methods
Materials
Recombinant murine MIP-3α was purchased from Peprotech (Rocky Hill, NJ) and GM-CSF 
from Cell Sciences (Canton, MA). Chemokines and growth factors were resuspended in 
sterile Dulbecco's Phosphate-Buffered Saline (DPBS) to a concentration of 1 mg/ml. Murine 
TLR9 ligand CpG ODN 1826, a Class B CpG oligonucleotide, was purchased from 
Invivogen (San Diego, CA). CpG was formulated in endotoxin-free water at 1 mg/ml. 
Calginate swabs used to remove mucus from mouse vaginal tracts were obtained from 
Fisher Scientific (Waltham, MA). Medroxyprogesterone acetate was obtained through the 
University of Washington pharmacy from Greenstone LLC (Peapack, NJ). Murine TNF-α 
and IL-1β Standard ELISA kits were purchased from Peprotech. Fluorescent yellow/green 
200 nm nanoparticles (FluoSpheres) 505/515 nm (excitation/emission) were purchased from 
Invitrogen.
Animals and intravaginal delivery of materials
Female C57Bl/6J mice (8-12 weeks old) were purchased from Jackson Laboratories. Prior to 
intravaginal administration, mice were subcutaneously administered 2 mg of 
medroxyprogesterone acetate (Depo-Provera®) formulated in sterile DPBS to reduce 
variability resulting from differences in stage of estrus cycle. All mice receiving treatments 
were anesthetized with isoflurane in an induction chamber. Genital tracts were flushed out 
three times with 50 μl sterile DPBS and vaginal lumens were swabbed with Calginate swabs 
to remove mucus. Mice were intravaginally administered 10 μg of chemokines, growth 
factors, adjuvants, or sterile DPBS (negative control) in 10 μl using a micropipette. Mice 
were transferred back to the induction chamber and hung upside down for 10 min to 
improve vaginal retention of materials. Animals were euthanized 24 h after treatments by 
carbon dioxide followed by cervical dislocation. Treatment groups, dosing, and animal 
experiment timelines are described in Figure 1a. All animal studies were approved by and in 
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compliance with guidelines set by the University of Washington Institutional Animal Care 
and Use Committee.
Antibodies
All antibodies were purchased from BD Biosciences (Franklin Lakes, NJ) unless otherwise 
indicated. Primary antibody-fluorochrome pairs used for staining and identifying cell 
populations included: APC anti-mouse CD11c, PE anti-mouse I-Ad/I-Ed (MHC II), PerCP-
Cy5.5 anti-mouse CD45, APC-Cy7 anti-mouse CD11b, PE-Cy7 anti-mouse CD8, and FITC 
anti-mouse F4/80 were purchased from eBioscience. Isotype antibodies used were APC 
Hamster IgG1 λ1, PE Rat IgG2b κ, APC-Cy7 Rat IgG2b κ PerCP-Cy5.5 Rat IgG2b κ FITC 
Rat IgG2a κ and PE-Cy7 IgG2a κ. LIVE/DEAD Fixable Green dead cell stain kit was 
purchased from Molecular Probes (Eugene, OR). For nanoparticle uptake studies, the 
following additional stains were used: Brilliant Violet-421 anti-mouse CD86 (BioLegend) 
and LIVE/DEAD Fixable Near-IR dead cell stain kit. Purified rat anti-mouse CD16/CD32 
was used to block Fc receptors (Fc block) on cells prior to cell surface staining. One Comp 
eBeads were purchased from eBioscience for antibody compensation and ArC amine 
reactive compensation bead kit was purchased from Molecular Probes for live/dead 
compensation.
Isolation of single cells from vaginal tissue and staining
Single cell suspensions were prepared from excised spleens and vaginal tissues using 
established techniques. Splenocytes were isolated by mechanical digestion of spleens with a 
syringe plunger in a 70 μm cell strainer on a petri dish with 5 ml of cRPMI (complete RPMI 
– RPMI 1640 + 10% heat inactivated FBS). Suspensions were restrained through a second 
70 μm filter and centrifuged in cRPMI at 1200 rpm for 5 min. Cells were subsequently 
incubated for 5 min with red blood cell (RBC) lysis buffer and further washed by 
centrifugation in cRPMI. Vaginal tracts including cervix, but not uterine horns, were 
dissected, placed in sterile DPBS on ice, and cut into small pieces (~2 mm diameter). 
Organs within each group (n = 3-6) were pooled to reduce variability. Cell isolation from 
vaginal tissues was adapted from previously published protocols33. Vaginal tissues were 
placed in 3 ml of digestion media, made with a 1:1 ratio of PBS and R15 (RPMI 1640 with 
FBS, 1% Penicillin Streptomycin) at a final collagenase from clostridium histolyticum 
(Sigma-Aldrich) concentration of 1 mg/ml. 3 μl of DNAse at 1 Unit/ml was added to tissue 
digestion preparations. Tissues were agitated for 30 min on an orbital shaker (New 
Brunswick Scientific, Incubator Shaker Series). Cell isolation suspensions were subject to 
further mechanical digestion through a blunt-end, 16-gauge needle and filtered through a 70-
μm cell strainer. Vaginal tissues were subjected to two rounds of chemical and mechanical 
digestion.
Cell suspensions were stained with a LIVE/DEAD Fixable Cell stain kit, washed, incubated 
with Fc block at 4°C for 15 min, and stained with antibody cocktails before washing and 
fixation with 1% paraformaldehyde. Samples were acquired on a FACSCanto2 with a 405-
nm violet laser, a 488-nm blue laser, and a 633-nm red laser.
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Tissue homogenization and cytokine measurements
The vaginal tract, including cervix, but not uterine horns was dissected 24 h after delivery of 
chemokines, growth factors, or adjuvants for tissue homogenization. Tissues were frozen at 
−80°C until use. Vaginal tracts were massed and placed in 0.5 ml of homogenization buffer 
(0.05% Triton X-100 in Hank's Balanced Salt Solution - HBSS buffer) and 2 ml of protease 
inhibitor. Tissues were fully homogenized using a Tissue Tearor (Biospec Products, Inc). 
Murine standard ELISA development kits for TNF-α and IL-1β (Peprotech Rocky Hill, NJ) 
were used to determine cytokine levels in tissue homogenates using standard procedures 
provided by the vendor.
Identification of draining lymph nodes
Draining lymph nodes, including the inguinal and iliac lymph nodes (Figure 1b,c), were 
identified by dye-guided lymph node mapping. Briefly, mice were subcutaneously injected 
in the footpad with a 5% (w/v) solution of Evans Blue prepared in sterile PBS. Mice were 
euthanized by CO2 and cervical dislocation after 15 minutes, to allow for lymphatic 
trafficking of the dye. As described by Ruddell et al., draining inguinal and iliac lymph 
nodes were identified visually34.
FluoSphere preparation and quantification
FluoSpheres (supplied at 2%, w/w) were buffer exchanged to remove sodium azide. Briefly, 
nanoparticles were washed three times with 70% EtOH in Amicon filters (10 KDa molecular 
weight cutoff) and twice with endotoxin-free water by centrifugation at 4,000 × g for 20 
min. FluoSpheres were collected and the concentration was determined using a TECAN 
fluorescence microplate reader. All particles were resuspended in endotoxin-free water to a 
final concentration of 0.5% (w/w) for intravaginal administration.
Intravaginal FluoSphere administration and imaging
Depo-provera treated mice were administered DPBS, GM-CSF, or CpG 24 h prior to 
intravaginal administration of nanoparticles. Mice were anesthetized using isoflurane in an 
induction chamber and intravaginally administered 10 μl of 0.5% (w/w) FluoSpheres. After 
24 h, mice were euthanized by CO2 and cervical dislocation. Vaginal tracts and the iliac and 
inguinal draining lymph nodes were dissected and placed on ice for imaging and flow 
cytometry analysis. A xenogen in vivo imaging system (iVis) was used to measure 
fluorescence at 505/515 nm (ex/em) for evaluating nanoparticle distribution in the vaginal 
tract, and in iliac and inguinal lymph nodes. Samples were acquired on a FACSCanto2. 
Samples were subsequently processed using an ImagestreamX Mark II imaging cytometer 
(Amnis, Seattle, WA) to visualize and evaluate cell internalization of nanoparticles.
Results
Mucosal APC subsets at homeostasis in the genital tract of female mice
Female mice treated with progesterone were maintained in the diestrous phase of the 
menstrual cycle. During diestrous, histological analysis shows that the murine lower female 
genital tract is comprised of a thinned epithelium overlying the lamina propria (Figure 1d). 
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Phenotypic analysis of murine vaginal cells by flow cytometry revealed that leukocytes 
(CD45+) accounted for up to 15% (11.03 ± 5.07 / mean ± S.D.) of the total cell population. 
Total mucosal DCs (CD45+MHCII+CD11c+) accounted for <1% (0.95 ± 1.16) of the total 
cells but up to 5% (3.93 ± 1.54) of total CD45+ leukocytes (Supplementary Fig. 1). Of this 
mucosal DC population, we observed that ~75% (75.33 ± 7.77) expressed the CD11b+ 
marker typical of subepithelial DCs whereas ~25% (24.68 ± 7.73) were CD11b negative 
(Supplementary Fig. 1), which is characteristic of Langerhans cells (LCs)35 (p < 0.0001, 
Student's t-test). Macrophages (CD45+MHCII+CD11c-CD11b+F4/80+) accounted for ~1% 
(0.67 ± 0.71) of the total cells and ~5% (5.78 ± 3.97) of the CD45+ cell population. In 
summary, we found that macrophages and dendritic cells have similar abundance of total 
mucosal leukocytes in the lower genital tract of female mice during diestrous.
GM-CSF treatment selectively enriches for CD11b+ dendritic cells
We tested the effect of delivering different agents topically to the vaginal mucosa to enrich 
for mucosal APCs. MIP-3α and GM-CSF were administered alone or in combination and 
compared to CpG, a synthetic adjuvant that recruits DCs by triggering local inflammation19 
(Figure 1a). Flow cytometry was used to measure the quantity and phenotype of different 
APC populations amongst total leukocyte cells (CD45+) collected from the vaginal tissue at 
24 h post-administration. Live, CD45+ cells were gated on MHC II, CD11c, CD11b, and 
F4/80 cell surface markers as described in Supplementary Figure 2.
At the doses used in our studies, the CpG and MIP-3α treatment groups did not significantly 
affect the magnitudes of any of the APC populations compared to the PBS controls (Figure 
2). Mucosal macrophages (CD45+MHC II+CD11c-CD11b+F4/80+) did not change in 
response to any of the intravaginal administrations (Figure 2a). In contrast, we found that the 
total mucosal DC (CD45+/MHCII+/CD11c+) population doubled to nearly 10% of the 
CD45+ leukocyte population upon administration of GM-CSF alone or in combination with 
the MIP-3α chemokine compared to the MIP-3α treatment group (Figure 2b). Surprisingly, 
we found that GM-CSF significantly expanded the CD11b+ DC populations compared to 
the synthetic adjuvant CpG used at an equivalent dose. In particular, CD11b+ mucosal 
dendritic cells (CD45+MHC II+CD11c+CD11b+F4/80−) were expanded an average of two 
fold by GM-CSF as compared to the PBS treatment group, and constituted up to 5.5% of the 
CD45+ leukocyte population (Figure 2c). We did not observe significant changes in the 
magnitude of mucosal Langerhans cells (CD45+/MHC II+/CD11c+/CD11b−) (Figure 2d). 
Although total tissue leukocytes (CD45+) appeared to increase in GM-CSF-treated mice, the 
difference was not statistically significant (Figure 2e).
Chemokines and growth factors do not impact systemic cell populations or vaginal 
cytokines
The reproductive mucosal tissues are highly vascularized, allowing for systemic distribution 
of intravaginally delivered agents. To understand if intravaginal administration of MIP-3α, 
GM-CSF, or CpG impacts systemic APC populations, we measured the magnitude of APC 
populations in the spleen by flow cytometry. At the doses used in our studies, we did not 
observe a significant difference in the total number of leukocytes or DCs (CD45+ MHC II+ 
CD11c+) in the spleen between any of our treatment groups (Figure 3a,b). Leukocytes 
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constituted about 50% of the total splenic cells and DCs represented only 1-3% abundance 
of these cells. Subpopulations of cells expressing CD11b and F4/80 were not observed in 
splenocyte-derived dendritic cells. These results suggest that the delivered factors did not 
impact systemic levels of leukocytes and dendritic cells.
During mucosal infections, expansion of APCs also results in production of inflammatory 
signals to modulate local immune responses36-38. We measured TNF-α and IL-1β cytokine 
levels in the vaginal tract 24-h post-topical administration of GM-CSF and CpG to evaluate 
if delivery of these agents and the resulting changes in the local immune cell populations 
caused inflammation. Our treatment groups show concentrations of TNF-α at ~1 pg/ml/mg 
and of IL-1β at ~5 pg/ml/mg, expressed per mass of vaginal tissue Figure 4). A trend 
towards increased IL-1β levels was observed in the CpG treatment group. We found no 
significant differences in the levels of these pro-inflammatory cytokines between mice that 
received GM-CSF compared to control mice treated with PBS. Therefore, despite significant 
enrichment of DCs and CD11b+ DCs up to 2-3 fold, we did not observe evidence of pro-
inflammatory cytokine secretion.
Fluorescent nanoparticles distribute in the vaginal tract and accumulate in draining lymph 
nodes
To evaluate if APCs retained their functional capacity to associate with or phagocytose 
nanoparticles, we measured uptake and trafficking of 200 nm fluorescent nanoparticles 24 
hours after vaginal tissues were administered with PBS, GM-CSF, or CpG. Fluorescence in 
the vaginal tract and iliac lymph nodes was quantified using LivingImage Software, and 
autofluorescence was normalized to the respective tissues from control mice. We observed 
high fluorescence intensity in the vaginal tract for all mice receiving nanoparticle 
administrations (Figure 5a). Quantification of fluorescence in the vaginal tracts 
demonstrated significant retention of intravaginally delivered nanoparticles in the genital 
lumen after 24 hours, with a trend towards CpG-treated mice retaining the most fluorescent 
nanoparticles (Figure 5c). We also analyzed for the presence of fluorescent nanoparticles in 
the iliac and inguinal lymph nodes, which drain the lower female genital tract. No 
fluorescence was observed in inguinal lymph nodes of mice from any treatment group (data 
not shown). However, we found fluorescent nanoparticles in the iliac lymph nodes of mice 
treated with PBS and GM-CSF but not CpG (Figure 5b). Although the mean fluorescence in 
the iliac lymph nodes was higher for GM-CSF treated mice, we observed no significant 
difference between our treatment groups (Figure 5d). In summary, nanoparticles delivered 
into the vagina were well retained for at least 24 hours and distributed to the iliac but not 
inguinal lymph nodes.
Dendritic cells internalize nanoparticles
To evaluate the function and phagocytic capacity of the total mucosal DC (CD45+/MHC II
+/CD11c+) population that was expanded in the vaginal tract by GM-CSF treatment, we 
assessed accumulation of fluorescent nanoparticles in these cells by flow cytometry. 
Fluorescent nanoparticles (10 μL of 0.5%, w/w) were administered intravaginally at 24h 
following initial treatment with PBS, CpG, or GM-CSF. After allowing an additional 24h 
for nanoparticle trafficking, the mice were sacrificed and total mucosal dendritic cells (MHC 
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II+ CD11c+) were quantified for NP fluorescence. In comparison to mice that did not 
receive NPs, we found that ~30% of DCs were NP+ (Figure 6a). At 48h post-administration 
of growth factors or adjuvants, total mucosal DCs remained elevated in GM-CSF treated 
mice compared to mice administered PBS or CpG (Figure 6b). We did not observe a 
difference in phagocytosis of NPs by mucosal DCs between treatment groups, indicating 
that treatment with GM-CSF did not stimulate enhanced uptake of particulates (Figure 6c).
To ascertain if the cell-associated fluorescence in our nanoparticle uptake studies was due to 
internalized or cell surface-associated nanoparticles, we analyzed samples from each 
treatment group on an Amnis ImageStream imaging flow cytometer. In these experiments, 
after nanoparticle treatment and cell isolation, cells were stained for viability and MHC II+ 
expression. Intracellular total fluorescence intensity was normalized to the total cell 
fluorescence to calculate an internalization score using the Amnis software. Cell surface 
intensity was defined by PE fluorescence, indicating MHC II+ antigen presenting cells. We 
calculated internalization scores of 1.7 for PBS, and 1.9 for GM-CSF and CpG treatment 
groups. These values indicate that approximately 65% of nanoparticle fluorescence was due 
to internal fluorescence in MHC II+ cells. The internalized particles were observed as 
punctate fluorescence in MHC II+ cells captured by the imaging flow cytometer (Figure 6d).
Discussion
In this study, we examined if intravaginal delivery of DC chemokines, growth factors, or 
synthetic adjuvants could expand mucosal dendritic cells and facilitate nanoparticle 
biodistribution to distal sites. We found that a low dose of GM-CSF doubled the frequency 
of total mucosal DCs (CD45+ MHC II+ CD11c+) to 10% of the leukocyte population in the 
vaginal mucosa. Furthermore, we observed a specific enrichment of subepithelial dendritic 
cells, which were identified by the presence of the CD11b surface marker from ~2% to ~5% 
of leukocytes. No change was observed in mucosal F4/80+ macrophages or CD11b- 
mucosal Langerhans cells. Overall, we observed a trend towards increased CD45+ 
leukocytes in GM-CSF-treated mice, but the difference was not statistically significant. 
Because DCs constitute only 2-5% of the CD45+ cell population, even a doubling of DCs 
would cause only a small change in the CD45+ leukocyte population, explaining why total 
leukocytes increased only marginally. Given what is known and described in the literature 
about GM-CSF, it is likely that increased proliferation or differentiation of local DCs and 
their precursors contributed to the expanded CD11b+ DC population, rather than recruitment 
from the periphery. However, our data do not distinguish between these possibilities, and 
future work will need to elucidate if GM-CSF acts strictly on mucosal cells to influence 
cellular infiltration of immune cells into the vagina.
While the exact function of each DC subset remains controversial, CD11b+ DCs have been 
previously demonstrated to be important for priming protective CD4+ T responses to 
vaginal infection by HSV-239. In this study by Zhao et al., mucosal Langerhans cells did not 
exhibit the ability to migrate to draining lymph nodes and prime T cells, implicating a 
potential tolerogenic role for these cells in the reproductive tissues. Evidence has also 
showed that GM-CSF-induced dendritic cells are monocyte-derived and are generated under 
inflammatory conditions. Unlike steady-state dendritic cells, which are CD11b-, these 
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inflammatory dendritic cells are CD11b+ and play an important role in shaping 
immunity40,41. Staining for other DC subset surface markers, such as CD14, may help 
further elucidate the specific polarization of these expanded DCs towards Th1 versus Th242. 
Thus, the GM-CSF-expanded population of CD11b+ dendritic cells in our study may play a 
role in enriching a cell population that has phagocytic and migratory capacity. As such, our 
results demonstrate that GM-CSF can be used to expand the local mucosal dendritic cell 
population in the vaginal tract within a 24-hour window.
Reproductive tissues are highly vascularized, potentially allowing for systemic delivery 
from topical administrations. To evaluate if vaginal administration of chemokines, growth 
factors, and adjuvants at the doses used in our animal models modulated immune cell 
populations in the periphery, we analyzed cell populations in the spleen. We found no 
statistically significant difference in levels of leukocytes and dendritic cells in the spleen 
between all treatment groups, suggested that intravaginally delivered agents acted locally 
and did not influence systemic immune cell populations.
Although MIP-3α is a well-defined DC chemoattractant, we found no significant increase in 
the total mucosal DC population in response to this chemokine, but this may be due to the 
low dose used in our studies. To our surprise we also found that the CpG-ODN 1826, a 
synthetic adjuvant that has been previously described to expand MHC II+ CD11b+ cells 
after intravaginal delivery, had no significant effect on the antigen presenting cell population 
in our study. This is likely a consequence of the lower dose used in our study as compared to 
other studies that deliver CpG at 20-100 μg15,43,44. That CpG was likely dosed too low in 
our study is also reflected by the finding that it did not stimulate TNF-α and IL-1β.
In general, the levels of TNF-α and IL-1βwere consistent with published data measuring 
these cytokines in the mouse reproductive mucosa at steady-state after Depo-Provera 
administration45. We did not observe an increase in TNF-α and IL-1β upon GM-CSF 
treatment, suggesting that while GM-CSF was able to expand the CD11b+ DC population, it 
did not stimulate increased cytokine secretion. This does not rule out, however, that 
increased dosing or co-delivery of GM-CSF and other maturation agents would induce 
cytokine secretion46,47.
Whole animal fluorescent imaging allowed us to macroscopically visualize biodistribution 
of fluorescent nanoparticles in the vaginal tract and lymph node tissues. Polystyrene 
nanoparticles were retained in the vaginal tract for at least 24-h post-topical administration. 
Furthermore, fluorescence imaging demonstrated that nanoparticles distributed to the iliac 
lymph nodes. As the iliac lymph nodes are one of the major draining lymph nodes from the 
reproductive tissues, we expect intravaginally administered materials to reach these tissues 
either by cell-associated or cell-free trafficking. Previous studies evaluating biodistribution 
of quantum dots demonstrated cell-free trafficking to the lumbar lymph nodes after 
intravaginal delivery48. Other studies have shown that nanoparticles in the range of 20-200 
nm are able to drain to lymph nodes where they are taken up by cells whereas NPs larger 
than 500nm were associated with tissue resident DCs originating from the site of injection49. 
In our study, we did not distinguish between cell-free and cell-associated trafficking of the 
nanoparticles. Future work may focus on differentiating between NP fluorescence in lymph 
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node resident immune cells versus migratory immune cells to elucidate modes of NP 
trafficking from the genital mucosa.
By analyzing the cell populations that showed nanoparticle fluorescence, we found that 
within all treatment groups about 30% of mucosal dendritic cells (MHC II+ CD11c+) 
associated with NPs. We observed no statistically significant difference in NP association 
with cells between treatment groups, indicating that phagocytic function of mucosal DC 
populations was not altered by any of the pre-treatments. We employed the Amnis 
ImageStream X imaging flow cytometer to ascertain if nanoparticle fluorescence in antigen 
presenting cells (MHC II+) was surface associated or intracellular. Our analysis showed that 
~65% of nanoparticle fluorescence was localized inside MHC class II+ cell populations for 
all treatment groups. This indicates that 24 hours after intravaginal administration, 
nanoparticles were still localized inside MHC II+ APCs. Punctate nanoparticle fluorescence 
in MHC II+ cells suggests that nanoparticles were likely sequestered in intracellular 
vesicles. Although we observed fluorescence in lymph nodes by Xenogen imaging, we were 
unable to detect nanoparticles in lymph node preparations after staining for mucosal DCs by 
conventional flow cytometry (data not shown). Given the low percentage of mucosal DCs in 
lymph nodes, it is likely that cell-associated nanoparticles were lost during sample staining 
and washing. Other groups that have attempted to detect particulates by flow cytometry after 
intravaginal administration of materials have also noted limited success identifying cell 
populations with particles in draining lymph nodes48. In conclusion, GM-CSF induced a 
greater number of DCs in the vaginal mucosa, but it did not alter their individual phagocytic 
capabilities. Thus, intravaginal administration of GM-CSF can be used to increase the 
number of nanoparticle-processing DCs in the vagina, which may be a useful strategy to 
improve the presentation and immunogenicity of topically delivered particulate vaccine 
antigens.
Conclusion
Our study aimed to describe the effect of exogenously delivered chemokines and growth 
factors on the local immune cell populations of the murine genital tract. We found that GM-
CSF increased the total mucosal DC population, specifically CD11b+ dendritic cells. 
Further, we found that the effects of GM-CSF were localized to the vaginal tract and did not 
impact systemic leukocyte levels. Finally, our results demonstrate that the enriched APC 
population in the vaginal tract is functional and able to phagocytose nanoparticulate 
materials. Extensions of our work will aim to optimize the in situ expansion of DCs using 
GM-CSF as a function of dose and administration schedule, and establish that its co-delivery 
with an antigen improves immune responses to a mucosal vaccine.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Administration timeline, lymph node mapping, and histologic features
Mice were cycled with Depo-Provera on Day 1 and intravaginally administered chemokines, 
growth factors, and adjuvants on Day 4. On day 5, tissues were harvested for cell analysis 
from all treatment groups; Nanoparticles (NPs) were administered to indicated mouse 
groups (continuing lines), which were further followed by fluorescence imaging to detect 
nanoparticle distribution and tissue processed for flow cytometry analysis on Day 6 (a). 
Evans Blue was subcutaneously injected in the footpad to map the inguinal (b) and iliac (c) 
lymph nodes. The uterine horns and vaginal tract are identified upon necropsy (c). 
Photomicrograph of H&E-stained mouse vaginal mucosa during progesterone-induced 
diestrous shows a thinned epithelium (d).
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Figure 2. Identification of expanded immune cell populations in the vagina
Murine vaginal cells were isolated and stained to identify cell populations 24 hours post-
vaginal administration of PBS, MIP-3α, GM-CSF, MIP-3α and GM-CSF, or CpG-ODN 
1826. Each symbol represents vaginal tracts pooled from 3-6 mice to reduce mouse-to-
mouse variability, and at least 3 independent experiments were performed per treatment. 
Effects of treatments are described on macrophages (a), total mucosal DCs (b), CD11b+ 
DCs (c), CD11b- DCs (d), and CD45+ leukocytes (e). Data were analyzed for statistical 
significance by a one-way ANOVA followed by a Bonferroni post-test (* p<0.05, ** 
p<0.01) and are displayed as mean ± S.E.M. Asterisks above lines indicate statistical 
significance between treatment groups.
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Figure 3. Spleen immune cell populations
Murine splenocytes were isolated and stained to identify immune cell populations following 
vaginal administration of PBS, MIP-3α, GM-CSF, MIP-3α and GM-CSF, or CpG-ODN 
1826. Each symbol represents spleens pooled from 3-6 mice to reduce mouse-to-mouse 
variability, and 3 or more independent experiments were performed per group. Effects of 
treatments are described on leukocytes (CD45+) (a) and splenic DCs (MHC II+ CD11c+) 
(b). Data were analyzed for statistical significance by a one-way ANOVA followed by a 
Bonferroni post-test and are displayed as mean ± S.E.M. No significant differences between 
any groups were found.
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Figure 4. Inflammatory cytokine levels in vaginal tissues
TNF-α and IL-1β cytokine production was measured in reproductive tissues using an 
ELISA. Tissues were homogenized and quantified by comparison to a standard, and 
normalized to tissue mass. No significant differences were observed in TNF-α (a) or IL-1β 
(b) cytokine levels between PBS, GM-CSF, and CpG topical administrations. Data were 
analyzed for statistical significance by a one-way ANOVA followed by a Bonferroni post-
test and are displayed as mean ± S.E.M.
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Figure 5. Xenogen imaging and fluorescence quantification
Vaginal tracts and draining lymph nodes were dissected 24-h after nanoparticle 
administration of mice pre-treated with PBS, GM-CSF, and CpG (n=3 per group). Tissues 
were imaged using a Xenogen in vivo imaging system (iVIS). Fluorescence was observed in 
the vaginal tract in all treatment groups (a) and in the iliac lymph nodes (b) in PBS and GM-
CSF treated animals. Fluorescence in the vaginal tract and iliac lymph nodes was quantified 
using the LivingImage Software (c,d). ND indicates that fluorescence was “not detected.” 
Data are displayed as mean ± S.E.M.
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Figure 6. Nanoparticle uptake in vaginal mucosal DCs
Total mucosal DCs were identified and nanoparticle uptake by these cells was quantified (a). 
Vaginal tracts from 3 mice were pooled within each group. GM-CSF treated animals 
displayed increased levels of total mucosal DCs (MHC II+ CD11c+) (b), but no significant 
difference was observed in NP phagocytosis by mucosal DCs between treatment groups (c). 
ImageStream imaging flow cytometry was performed to evaluate if nanoparticles were 
internalized in mucosal MHC II+ cells. A representative image of nanoparticle 
internalization in MHC II+ cells is shown (d). Bright field (BF), PE, and FITC channels 
show live cells, MHC II cell surface staining, and internal NP fluorescence, respectively. 
The composite image shows punctate NPs in MHC II+ cells.
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